Skip to search formSkip to main contentSkip to account menu

MG 98

Known as: MG-98, MG-98 oligonucleotide, MG98 
A second-generation, mixed-backbone, phosphorothioate antisense oligonucleotide (ODN) with potential antitumor activity. MG 98 is a highly specific… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligodeoxyribonucleotides, Antisense

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
MG 98 , a Second-Generation DNMT 1 Inhibitor , in the Treatment of Advanced Renal Cell Carcinoma
Department of Internal Medicine, The University of Texas Medical School/ Memorial Hermann Cancer Center, Houston, Texas, USA… 
2009
2009
Phase I Study of MG 98 , an OligonucleotideAntisense Inhibitor of Human DNAMethyltransferase 1 , Given as a 7-Day Infusion in Patients with Advanced SolidTumors
Purpose:To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of… 
2008
2008
Biological Study of MG 98 , an Oligodeoxynucleotide Antisense to DNAMethyltransferase 1 , in Patients with High-RiskMyelodysplasia andAcuteMyeloid Leukemia
Purpose: Epigenetic silencing via aberrant promoter DNA hypermethylation of normal genes has been described as a leukemogenic… 
2007
2007
The Promise of Epigenetic Therapy
2007
2007
Gateways to clinical trials.
1E10, 101M; AAV-ASPA, agomelatine, aliskiren fumarate, alvimopan hydrate, ambrisentan, apaziquone, axitinib; Becatecarin… 
2005
2005
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.
3070 Background: DNA methylation has been postulated to play an important role in tumour progression and increased DNA… 
2004
2004
443 Decreased expression of DNMT1 at the mRNA level following 7 day infusion of the antisense compound MG98 in a phase I study
2001
2001
Technology evaluation: MG-98, MethylGene.
  • Z. Zhang
  • Current opinion in molecular therapeutics (Print)
  • 2001
  • Corpus ID: 33182883
MethylGene and MGI Pharma are codeveloping MG-98, a second-generation antisense oligonucleotide which inhibits mRNA produced by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)